Protagonist Therapeutics
PTGX
167 hedge funds and large institutions have $1.57B invested in Protagonist Therapeutics in 2023 Q2 according to their latest regulatory filings, with 44 funds opening new positions, 59 increasing their positions, 48 reducing their positions, and 14 closing their positions.
214% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 14
118% more call options, than puts
Call options by funds: $49.7M | Put options by funds: $22.8M
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
28% more capital invested
Capital invested by funds: $1.22B → $1.57B (+$342M)
23% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 48
22% more funds holding
Funds holding: 137 → 167 (+30)
4.67% less ownership
Funds ownership: 103.77% → 99.1% (-4.7%)
Top Buyers
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$47.5M |
| 2 |
CAC
Cowen and Company
New York
|
+$41.5M |
| 3 |
State Street
Boston,
Massachusetts
|
+$28.5M |
| 4 |
RI
RTW Investments
New York
|
+$20.4M |
| 5 |
Holocene Advisors
New York
|
+$20.1M |
Top Sellers
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$31.7M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$30.1M |
| 3 |
Morgan Stanley
New York
|
-$24.8M |
| 4 |
Millennium Management
New York
|
-$19.3M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$15.4M |
PTGX Hedge Fund Activity: Q2 2023 in Review
167 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q2 2023, worth a combined $1.57B — up 28% from $1.22B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new PTGX positions and 14 closed out — a net gain of 30 holders — while 59 added to existing stakes and 48 trimmed.
The largest buyer was Farallon Capital Management, adding an estimated $47.5M. The largest seller was Adage Capital Partners, cutting an estimated $31.7M.
- 167 institutional investors held Protagonist Therapeutics (PTGX) as of Q2 2023, up from 137 in Q1 2023.
- Funds reported $1.57B of Protagonist Therapeutics stock for Q2 2023, up 28% quarter-over-quarter.
- 44 funds opened new Protagonist Therapeutics positions in Q2 2023 and 14 closed out, a net change of +30 holders.
- The largest Protagonist Therapeutics buyer in Q2 2023 was Farallon Capital Management, an estimated $47.5M added.
- The largest Protagonist Therapeutics seller in Q2 2023 was Adage Capital Partners, an estimated $31.7M sold.
Based on aggregated 13F filings for Q2 2023.